Related Experiment Video

Updated: Apr 28, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K

MEK inhibitor effective against proliferation in breast cancer cell

Yan Zhou1, Hai-Yan Hu, Wei Meng

  • 1Oncology Department of Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, No 600 Yishan Road Xuhui, Shanghai City, China, 200233.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|June 19, 2014
PubMed

Insights

The MEK inhibitor AZD6244 halts breast cancer cell growth by increasing miR-203, which targets CUL1. This pathway is crucial for AZD6244

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The targeted small-molecule drug AZD6244 inhibits MEK1/2, showing efficacy in various cancers.
  • Understanding the molecular mechanisms of AZD6244 in breast cancer is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the role of microRNA-203 (miR-203) in mediating the anti-cancer effects of AZD6244 in breast cancer cells.
  • To identify the downstream targets of miR-203 involved in the AZD6244 signaling pathway.

Main Methods:

  • Treatment of breast cancer cell lines (MDA-MB-231, HCC1937) with AZD6244.
  • MicroRNA arrays and quantitative RT-PCR to assess miR-203 expression.
  • Bioinformatics and luciferase activity assays to confirm CUL1 as a direct target of miR-203.

Main Results:

  • AZD6244 treatment repressed cell growth, induced apoptosis, and caused G1-phase arrest in breast cancer cells.
  • miR-203 expression was significantly upregulated following AZD6244 treatment.
  • CUL1 was identified as a direct target of miR-203, and its inhibition reversed AZD6244's cytotoxicity.

Conclusions:

  • miR-203 mediates the cytotoxic effects of AZD6244 in breast cancer cells.
  • The MEK/ERK/miR-203/CUL1 signaling pathway is implicated in AZD6244-induced breast cancer cell death.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

28.8K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K